Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary Novartis has signed a deal with Abogen Biosciences, a China-based biotech, for rights to ABO-2203, an mRNA-encoded T-cell engager that targets both CD3 and CD19. The payment is $575
Summary Shionogi agreed on October 5, 2026, to acquire IntraBio, a Texas-based rare disease company, for $2 billion in cash. The deal gives Shionogi full control of Aqneursa, a treatment
Summary AstraZeneca is investing $2 billion in Summit Therapeutics. The deal was announced September 29, 2026. Specifically, it gives AstraZeneca roughly 12% equity in Summit. In return, AstraZeneca gets a
Summary The White House has announced “most-favored-nation” pricing agreements with 26 pharmaceutical companies over the past year. The stated goal is to bring US drug prices closer to prices paid
Summary The Trump administration extended its Medicaid low-price model on September 1, 2026, adding mid-cap biotechs to a program previously limited to large pharmaceutical companies. Manufacturers sign pricing agreements in
Summary Eli Lilly agreed to acquire Merida Biosciences for $2.9 billion, announced August 31, 2026. Merida’s lead drug, MER511, targets the autoantibodies that drive Graves disease. The program entered Phase
Summary Eli Lilly and Novo Nordisk compete with FDA-approved GLP-1 drugs for weight loss — injectables and pills — but a KFF survey shows 55% of insured users find these
On July 31, 2026, the Health Resources and Services Administration published a revised Notice Regarding the 340B Rebate Model Pilot Program in the Federal Register. The pilot, scheduled to take
Summary Argenx has agreed to buy Forte Biosciences for up to $2.2 billion. The all-cash offer is $77 per share, a premium of about 41%. It was announced on 27
Summary The U.S. administration has threatened tariffs of up to 200% on imported generic drugs. Branded medicines have seen limited impact so far. In part, that is because 17 drugmakers